UNIQURE NV (QURE)

NL0010696654 - Common Stock

18.08  +0.14 (+0.78%)

After market: 18.15 +0.07 (+0.39%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to QURE. QURE was compared to 561 industry peers in the Biotechnology industry. QURE has a bad profitability rating. Also its financial health evaluation is rather negative. QURE is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year QURE has reported negative net income.
QURE had a negative operating cash flow in the past year.
QURE had negative earnings in 4 of the past 5 years.
QURE had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of QURE (-37.09%) is comparable to the rest of the industry.
QURE has a worse Return On Equity (-429.05%) than 78.38% of its industry peers.
Industry RankSector Rank
ROA -37.09%
ROE -429.05%
ROIC N/A
ROA(3y)-4.78%
ROA(5y)-15.75%
ROE(3y)-39.95%
ROE(5y)-41.91%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of QURE (7.15%) is better than 73.33% of its industry peers.
QURE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QURE has more shares outstanding
The number of shares outstanding for QURE has been increased compared to 5 years ago.
QURE has a worse debt/assets ratio than last year.

2.2 Solvency

QURE has an Altman-Z score of -1.62. This is a bad value and indicates that QURE is not financially healthy and even has some risk of bankruptcy.
QURE has a Altman-Z score of -1.62. This is comparable to the rest of the industry: QURE outperforms 53.69% of its industry peers.
A Debt/Equity ratio of 8.56 is on the high side and indicates that QURE has dependencies on debt financing.
QURE's Debt to Equity ratio of 8.56 is on the low side compared to the rest of the industry. QURE is outperformed by 84.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.56
Debt/FCF N/A
Altman-Z -1.62
ROIC/WACCN/A
WACC7.22%

2.3 Liquidity

QURE has a Current Ratio of 6.51. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of QURE (6.51) is better than 64.68% of its industry peers.
A Quick Ratio of 6.51 indicates that QURE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.51, QURE is doing good in the industry, outperforming 64.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.51
Quick Ratio 6.51

More info and screens

4

3. Growth

3.1 Past

The earnings per share for QURE have decreased by -3.25% in the last year.
Looking at the last year, QURE shows a very negative growth in Revenue. The Revenue has decreased by -74.43% in the last year.
QURE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.99% yearly.
EPS 1Y (TTM)-3.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.6%
Revenue 1Y (TTM)-74.43%
Revenue growth 3Y-24.96%
Revenue growth 5Y6.99%
Sales Q2Q%62.54%

3.2 Future

QURE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
The Revenue is expected to grow by 49.16% on average over the next years. This is a very strong growth
EPS Next Y35.42%
EPS Next 2Y21.55%
EPS Next 3Y16.23%
EPS Next 5Y10.53%
Revenue Next Year86.7%
Revenue Next 2Y33.48%
Revenue Next 3Y78.84%
Revenue Next 5Y49.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

QURE's earnings are expected to grow with 16.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.55%
EPS Next 3Y16.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QURE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIQURE NV

NASDAQ:QURE (1/6/2025, 8:00:01 PM)

After market: 18.15 +0.07 (+0.39%)

18.08

+0.14 (+0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)N/A N/A
Inst Owners73.06%
Inst Owner Change0%
Ins Owners1.83%
Ins Owner Change0.14%
Market Cap881.22M
Analysts84.21
Price Target32.36 (78.98%)
Short Float %9.8%
Short Ratio1.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.37%
Min EPS beat(2)9.38%
Max EPS beat(2)11.35%
EPS beat(4)2
Avg EPS beat(4)3.36%
Min EPS beat(4)-4.17%
Max EPS beat(4)11.35%
EPS beat(8)3
Avg EPS beat(8)-28.14%
EPS beat(12)6
Avg EPS beat(12)-6.53%
EPS beat(16)8
Avg EPS beat(16)1.76%
Revenue beat(2)1
Avg Revenue beat(2)-4.31%
Min Revenue beat(2)-67%
Max Revenue beat(2)58.38%
Revenue beat(4)3
Avg Revenue beat(4)10.52%
Min Revenue beat(4)-67%
Max Revenue beat(4)58.38%
Revenue beat(8)4
Avg Revenue beat(8)15.49%
Revenue beat(12)5
Avg Revenue beat(12)22.73%
Revenue beat(16)6
Avg Revenue beat(16)14.99%
PT rev (1m)66.99%
PT rev (3m)65.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30.88%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.71%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)-12.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.83
P/FCF N/A
P/OCF N/A
P/B 15.79
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.96
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.68
OCFYN/A
SpS0.59
BVpS1.15
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.09%
ROE -429.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.15%
FCFM N/A
ROA(3y)-4.78%
ROA(5y)-15.75%
ROE(3y)-39.95%
ROE(5y)-41.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 8.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.02%
Cap/Sales 18.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.51
Quick Ratio 6.51
Altman-Z -1.62
F-Score1
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)168.9%
Cap/Depr(5y)138.97%
Cap/Sales(3y)21.7%
Cap/Sales(5y)36.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.6%
EPS Next Y35.42%
EPS Next 2Y21.55%
EPS Next 3Y16.23%
EPS Next 5Y10.53%
Revenue 1Y (TTM)-74.43%
Revenue growth 3Y-24.96%
Revenue growth 5Y6.99%
Sales Q2Q%62.54%
Revenue Next Year86.7%
Revenue Next 2Y33.48%
Revenue Next 3Y78.84%
Revenue Next 5Y49.16%
EBIT growth 1Y-0.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.02%
EBIT Next 3Y15.51%
EBIT Next 5Y18.43%
FCF growth 1Y-20.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.59%
OCF growth 3YN/A
OCF growth 5YN/A